Scrip code	532167
NSE Symbol	
MSEI Symbol	
ISIN*	INE501C01015
Name of company	OMKAR PHARMACHEM LIMITED
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2021
Date of end of financial year	31-03-2022
Date of board meeting when results were approved	14-02-2022
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-02-2022
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Third quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical
Start date and time of board meeting	14-02-2022 17:30
End date and time of board meeting	14-02-2022 18:10
Whether cash flow statement is applicable on company	
Type of cash flow statement	

Declaration of unmodified opinion or statement on impact of audit qualification

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)		
А	Date of start of reporting period	01-10-2021	01-04-2021		
В	Date of end of reporting period	31-12-2021	31-12-2021		
С	Whether results are audited or unaudited	Unaudited	Unaudited		
D	Nature of report standalone or consolidated	Standalone	Standalone		
Part I					
1	Income				
	Revenue from operations	13.5	40		
	Other income	0			
	Total income	13.5	40		
2	2 Expenses				
(a)	Cost of materials consumed	0			
(a) (b)	Cost of materials consumed Purchases of stock-in-trade	0			
( )					
(b)	Purchases of stock-in-trade Changes in inventories of finished goods, work-in-	0	13.1		
(b) (c)	Purchases of stock-in-trade Changes in inventories of finished goods, work-in- progress and stock-in-trade	0	13.: 2.2		
(b) (c) (d)	Purchases of stock-in-trade Changes in inventories of finished goods, work-in- progress and stock-in-trade Employee benefit expense	0 0 4.38			
(b) (c) (d) (e)	Purchases of stock-in-trade Changes in inventories of finished goods, work-in- progress and stock-in-trade Employee benefit expense Finance costs	0 0 4.38 0	2.2		

Total other expenses	0.93	6.79
Total expenses	5.38	22.28

Financial Results – Ind-AS					
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)		
А	Date of start of reporting period	01-10-2021	01-04-2021		
В	Date of end of reporting period	31-12-2021	31-12-2021		
С	Whether results are audited or unaudited	Unaudited	Unaudited		
D	Nature of report standalone or consolidated	Standalone	Standalone		
Part I					
3	Total profit before exceptional items and tax	8.12	18.22		
4	Exceptional items	0	C		
5 Total profit before tax		8.12	18.22		
7	Tax expense				
8	Current tax	0	0		
9 Deferred tax		0	C		
10	Total tax expenses	0	(		
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	(		
14	Net Profit Loss for the period from continuing operations	8.12	18.22		
15	Profit (loss) from discontinued operations before tax	0	(		
16	Tax expense of discontinued operations	0	C		
17	Net profit (loss) from discontinued operation after tax	0	(		
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	(		
21	Total profit (loss) for period	8.12	18.22		
22	Other comprehensive income net of taxes	0	0		

.

Financial Results – Ind-AS				
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
А	Date of start of reporting period	01-10-2021	01-04-2021	
В	Date of end of reporting period	31-12-2021	31-12-2021	
С	Whether results are audited or unaudited	Unaudited	Unaudited	
D	Nature of report standalone or consolidated	Standalone	Standalone	
Part I				
23	Total Comprehensive Income for the period	8.12	18.22	
24	24 Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
25 Total Comprehensive income for the period attributable to				
	Comprehensive income for the period attributable to owners of parent	0	0	
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0	
26	26 Details of equity share capital			
	Paid-up equity share capital	1008.37	1008.37	
	Face value of equity share capital	10	10	
27	27 Details of debt securities			
28	Reserves excluding revaluation reserve			
29	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	0.081	0.181	

L			
	Diluted earnings (loss) per share from continuing operations	0.081	0.181
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	0.081	0.181
	Diluted earnings (loss) per share from continuing and discontinued operations	0.081	0.181
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results	Textual Information(1)	

	Text Block
	1. The above results have been reviewed by the audit Committee & Approved by the board of Directors at their respective meeting held on 14th February2022.
Textual Information (1)	2. Corresponding previous periods figures are regrouped/rearranged where-ever necessary to make them Comparable.
Textual Information(1)	3. The IND-AS regarding segments reporting is not applicable to the company as there is no segements.
	4. The Financial Results for the quarter and Nine Months ended on December 31, 2021 has been prepared in accordance with IND-AS specified under section 133 of the Companies Act, and rules made there under.

Г

	Particulars	3 months/ 6 month ended (dd- mm-yyyy)	Year to date figures for current period ended (dd mm-yyyy)
	Date of start of reporting period	01-10-2021	01-04-2021
	Date of end of reporting period	31-12-2021	31-12-2021
	Whether accounts are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
1	Segment Revenue (Income)		
	(net sale/income from each segment should be discle	osed)	
	Total Segment Revenue		
	Less: Inter segment revenue		
	Revenue from operations		
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from eac	h segment	
	Total Profit before tax		
	i. Finance cost		
	ii. Other Unallocable Expenditure net off Unallocable income		
	Profit before tax		
3	(Segment Asset - Segment Liabilities)		•
	Segment Asset		
	Total Segment Asset		
	Un-allocable Assets		

٦

	Net Segment Asset	
4	Segment Liabilities	
	Segment Liabilities	
	Total Segment Liabilities	
	Un-allocable Liabilities	
	Net Segment Liabilities	
	Disclosure of notes on segments	